Phathom Stocks Skyrocket 53% After FDA Approval!
StockSavvyFriday, Jun 6, 2025 11:54 am ET
1min readPhathom Pharmaceuticals, Inc. surged 53.31% intraday after the FDA approved its VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, and VOQUEZNA tablet applications, and the company launched commercial sales for VOQUEZNA targeting Erosive GERD and H. pylori indications in the fourth quarter of 2023.
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
Comments
No comments yet